What this study adds:
- Patients who develop clinical AKI following cisplatin infusion exhibit
metabolic differences compared to patients who do not
- We reveal glycine, hippuric acid sulfate, 3-hydroxydecanedioc acid,
and suberate as potential predictive markers of predisposition to
cisplatin-induced AKI
- Identification of several urine and serum metabolites exhibiting early
alterations after cisplatin infusion are potential markers of
subclinical nephrotoxicity